HC Wainwright Brokers Lower Earnings Estimates for Liquidia

Liquidia Corporation (NASDAQ:LQDA) – Investment analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for Liquidia in a note issued to investors on Thursday, August 13th. HC Wainwright analyst A. Fein now forecasts that the company will earn $1.01 per share for the quarter, down from their previous forecast of $1.15. The consensus estimate for Liquidia’s current full-year earnings is $3.02 per share.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The company had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 237.10%. The firm’s revenue was up 1842.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.49) earnings per share.

Several other research analysts also recently commented on the company. Jefferies Financial Group restated a “buy” rating and issued a $60.00 target price on shares of Liquidia in a research note on Monday, May 11th. Wall Street Zen lowered Liquidia from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Stephens set a $130.00 target price on shares of Liquidia in a research report on Friday, July 24th. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Finally, Wells Fargo & Company increased their target price on Liquidia from $62.00 to $108.00 and gave the company an “overweight” rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $98.08.

Liquidia Stock Performance

Shares of LQDA stock opened at $72.10 on Friday. Liquidia has a 12 month low of $21.15 and a 12 month high of $93.61. The stock has a market capitalization of $6.41 billion, a P/E ratio of 52.63 and a beta of 0.58. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The firm’s 50 day moving average is $78.42 and its 200 day moving average is $55.00.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Liquidia by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares during the period. Goldman Sachs Group Inc. grew its position in Liquidia by 10.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after purchasing an additional 16,022 shares during the last quarter. Creative Planning boosted its stake in shares of Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after purchasing an additional 7,765 shares during the period. Finally, Legal & General Group Plc grew its holdings in shares of Liquidia by 13.4% in the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after purchasing an additional 11,111 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Jason Adair sold 688 shares of the company’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $87.53, for a total transaction of $60,220.64. Following the sale, the insider owned 216,438 shares of the company’s stock, valued at $18,944,818.14. This represents a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Krepp sold 7,864 shares of Liquidia stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $562,354.64. Following the completion of the transaction, the insider owned 117,178 shares of the company’s stock, valued at approximately $8,379,398.78. This trade represents a 6.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,756,861 shares of company stock valued at $122,981,112 in the last ninety days. Company insiders own 25.60% of the company’s stock.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove a sharp increase in revenue and profitability. Liquidia reported approximately $171.7 million in quarterly revenue, including about $170.4 million from YUTREPIA, while net income reached roughly $74.7 million. Management also reaffirmed its goal of generating more than $1 billion in net revenue in 2027. LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
• Positive Sentiment: Analysts raised their targets following the earnings report. Needham increased its target to $110 from $70 and maintained a buy rating, while BTIG raised its target to $111 from $109 and reiterated buy. Bank of America lifted its target to $92 from $79, although it retained a neutral rating. Liquidia Stock Price Expected to Rise, Needham Analyst Says
• Neutral Sentiment: Lifesci Capital reaffirmed a market perform rating but set a $90 price target, indicating potential upside while signaling a more cautious view than the buy-rated analysts. Liquidia Earns Market Perform Rating from Lifesci Capital
• Negative Sentiment: Adjusted earnings per share of $0.74 were slightly below the company’s reported consensus estimate of $0.76, even though revenue exceeded expectations. The modest earnings miss, elevated expectations after a 155% year-to-date rally, and anticipated higher second-half research and development spending for the L606 Phase 3 program contributed to the selloff and a gap lower in the shares. Liquidia Shares Gap Down on Disappointing Earnings

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).